Multimodal exercise program for middle-aged and older adults with diabetic sarcopenia

Effects of Multimodal Training on Muscle Function and Glucose Metabolism in Middle-Aged and Older Adults With Type 2 Diabetes Mellitus and Sarcopenia

Not applicable Interventional Chung Shan Medical University · NCT07398495

This program will try a 12-week multimodal exercise plan with supervised, home-based, and digital support to improve muscle function and metabolic health in people aged 45–85 who have type 2 diabetes and sarcopenia.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment128 (estimated)
Ages45 Years to 85 Years
SexAll
SponsorChung Shan Medical University Academic / other
Locations1 site (Taichung, Taiwan)
Trial IDNCT07398495 on ClinicalTrials.gov

What this trial studies

This randomized controlled trial will enroll 128 adults with type 2 diabetes and sarcopenia and randomly assign them to a multimodal exercise intervention or a control group receiving standard health education. The 12-week intervention combines supervised training sessions, guided home exercises, and digital support plus educational materials. Outcomes including physical function, sarcopenia risk measures, metabolic control, and quality of life will be measured at baseline, week 12, and week 24. The trial is conducted at Chung Shan Medical University Hospital in Taichung, Taiwan and focuses on middle-aged and older Asian participants.

Who should consider this trial

Good fit: Adults aged 45–85 with diagnosed type 2 diabetes and sarcopenia who are on a stable regimen of oral hypoglycemic agents and can communicate in Mandarin or Taiwanese and attend supervised sessions are ideal candidates.

Not a fit: Patients with severe comorbidities such as end-stage renal disease, active diabetic foot ulcers, recent stroke, major limb limitations that prevent exercise, severe cognitive impairment, or uncontrolled psychiatric illness are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the program could slow muscle loss, increase strength and physical function, and improve glycemic control and quality of life for people with T2DM and sarcopenia.

How similar studies have performed: Previous resistance and multimodal exercise programs have shown improvements in muscle mass, strength, and metabolic markers in older adults with sarcopenia and diabetes, though data specifically in Asian T2DM populations are more limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosed with both Type 2 Diabetes Mellitus (T2DM) and sarcopenia.
* Maintained on a stable regimen of oral hypoglycemic agents.
* Aged 45 years or older.
* Capable of communicating effectively in Mandarin or Taiwanese.
* Willing to provide informed consent or have it obtained from a legally authorized representative.

Exclusion Criteria:

* • Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations).

  * Communication barriers or severe emotional/psychological issues (e.g., uncontrolled depression or severe mental illness).
  * Severe cognitive impairment (e.g., dementia).
  * End-stage renal disease (ESRD).
  * Major comorbidities or complications, including active diabetic foot ulcers, amputation, recent myocardial infarction, severe autonomic neuropathy, or a history of stroke within the last 3 years.

Where this trial is running

Taichung, Taiwan

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Type 2 Diabetes MellitusSarcopenia
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.